In today’s briefing:
- Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down
- ASRT: Low Valuation Growth
Pharmaessentia Corp (6446 TT): Key Marketed Drug Besremi Is Showing No Sign of Slow Down
- Pharmaessentia Corp (6446 TT) is on a robust growth path following the U.S. launch of its key drug Besremi for polycythemia vera (PV) in December 2021.
- The company has reported July net revenue of NT$348.5 million, an increase of 937% and 26% from July 2021 and June 2022, respectively.
- Besremi has further label expansion opportunity as the drug is undergoing clinical trials for additional indications including essential thrombocythemia (ET), myelofibrosis, and chronic hepatitis.
ASRT: Low Valuation Growth
- Reporting better than expected Q2 results was not enough to keep investors interested after the earnings release
- ASRT is in the process of broadening its sales channel for its recently acquired drug, Otrexup. ASRT should begin to generate a return on the drug in 2H2022
- Indocin volume rose by approximately 7 percent sequentially. ASRT had increased prices in the second half of last year with investors concerned ASRT could face pushback from hospitals on pricing
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
